Lab In The news

Signal Alert: Startup Seeks Community Funders for AAV Immuno-Gene Therapy

April 24, 2025 Siren Biotechnology at UCSF is developing the first universal AAV-based gene therapy for solid tumors, starting with brain cancers like high-grade gliomas. To fund its upcoming first-in-human clinical trial, Siren launched a community investment round via Wefunder, seeking $50,000–$5 million. Its lead therapy, SRN-101, combines gene therapy with cytokine immunotherapy and has […]
Read more